Send to

Choose Destination
Br J Cancer. 2016 Feb 16;114(4):463-8. doi: 10.1038/bjc.2016.11. Epub 2016 Feb 4.

High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.

Wang H1,2, Wang L1,2, Chi PD1,3, Wang WD1,2, Chen XQ1,2, Geng QR1,2, Xia ZJ1,2, Lu Y1,2.

Author information

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People's Republic of China.
Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.
Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, People's Republic of China.



Interleukin-10 (IL-10) is a inhibiting inflammatory cytokine that plays an important role in immune suppressive microenvironment in multiple myeloma (MM). Whether the level of serum IL-10 could predict treatment response and survival outcomes or not needs to be investigated in MM patients.


The level of IL-10 in serum was measured using enzyme-linked immunosorbent assay in 188 patients with newly diagnosed MM.


The best cutoff value for IL-10 in predicting survival is 169.69 pg ml(-1) with an area under the curve (AUC) value of 0.747 (P<0.001). In all, 92 patients (48.9%) were classified as high-IL-10 group (>169.96 pg ml(-1)) and 96 patients (51.1%) as low-IL-10 group (⩽169.96 pg ml(-1)). The overall response rate (ORR) was 79.2% in low-IL-10 group, significantly higher than that in high-IL-10 group (53.3%, P<0.001). Patients in low-IL-10 group had significantly better survival compared with those in high-IL-10 group (3-year PFS rate: 69.3% vs 13.3%, P<0.001; 3-year OS rate: 93.6% vs 51.9%, P<0.001). Multivariate analysis revealed that serum IL-10 level >169.96 pg ml(-1) at diagnosis and certain cytogenetic abnormalities were two adverse factors for PFS and OS.


Our data suggest that serum IL-10 at diagnosis is a novel, powerful predictor of prognosis for MM.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center